Our Pipeline

Our goal is the generation of novel therapeutic vaccines directed against chronic diseases and beyond.

Building on the proprietary WISIT platform technology, we are currently developing such therapeutic neoglucoconjugate vaccines for several indications, with Parkinson’s disease as our lead indication and aggregated aSynuclein as prime target molecule.